Moleculin Biotech, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Walter V. Klemp
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5300 Memorial Drive Houston TX United States of America 77007
- IPO Date
- Jun 2, 2016
- CIK
- 0001659617
- Website
- moleculin.com
- Similar Companies
- Business
- Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for hard-to-treat tumors and viruses. Founded in 2010 and headquartered in Houston, Texas, the company advances a late-stage pipeline of therapeutic candidates primarily in oncology and infectious diseases. Its core product portfolio includes Annamycin, a next-generation non-cardiotoxic anthracycline designed to overcome multidrug resistance, currently under evaluation in a pivotal Phase 3 clinical trial for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. Additional clinical-stage candidates include WP1066, an immune and transcription modulator targeting brain tumors, pancreatic cancer, and other cancers, and WP1122, an antimetabolite aimed at treating viral infections and certain cancer indications. Moleculin's technologies are built around these three platforms with six drug candidates, three of which have demonstrated human activity in clinical trials. Recent major developments include the initiation and ongoing enrollment of the MIRACLE Phase 3 trial for Annamycin in combination with cytarabine (AnnAraC) for refractory or relapsed AML patients, with the trial expanding globally to sites across Europe, the US, and the Middle East. The company obtained orphan drug designations and fast-track status for Annamycin from the FDA, affirming its regulatory progress. In 2025, Moleculin announced a reverse stock split (1-for-25) effective December 1 to consolidate shares, following a significant stock price decline over the prior year. The company also secured a patent from the Australian Patent Office for Annamycin, strengthening its intellectual property position. Additionally, Moleculin completed a $6.5 million at-the-market equity offering to support its clinical programs and operational activities. Despite facing Nasdaq compliance challenges related to stockholders' equity, Moleculin plans to appeal the delisting determination while continuing to advance its pivotal studies. Moleculin operates primarily in the pharmaceutical and biotechnology sector, targeting healthcare providers, hospitals, and research institutions in North America, Europe, and the Middle East. Its development pipeline addresses critical unmet needs in hematology, oncology, and infectious diseases, focusing on patient populations with limited treatment options. The company maintains a research and development focus, with its lead clinical programs undergoing regulatory review and late-stage clinical evaluation. Overall, Moleculin Biotech is a Houston-based biopharmaceutical firm specializing in innovative cancer and antiviral therapies, pursuing strategic clinical development, regulatory milestones, and financing initiatives to advance its product candidates toward commercialization in global markets. The company's latest operational emphasis is on completing its Phase 3 Annamycin trial and expanding its clinical footprint internationally through partnerships and clinical site expansion.
Company News
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Moleculin Announces Pricing of $9.3 Million Public Offering
Moleculin Announces Pricing of $9.3 Million Public Offering
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
Why is Moleculin Stock Falling Today?
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial